Global /China /Healthcare /Biotechnology /2637

Fujian Haixi Pharmaceuticals Co., Ltd.

2637

• SHEK: 2637 • Delayed

261.00HKD 9.2%

33.31 USD

As of 14 June 2026, Fujian Haixi Pharmaceuticals Co., Ltd. has a market cap of $2.4B USD, ranking #6263 globally and #1432 in China. It ranks #493 in the Healthcare sector, and #90 in the Biotechnology industry.

Global Rank

6263

Country Rank

1432

Sector Rank

493

Industry Rank

Key Stats

Market Cap

$2.4BUSD

18.81B HKD

Enterprise Value

$2.23BUSD

17.45B HKD

Revenue (TTM)

$82.69MUSD

648.05M HKD

EBITDA (TTM)

$27.72MUSD

217.21M HKD

Net Income (TTM)

$25.14MUSD

197.0M HKD

EBITDA Margin

34%

Profit Margin

30%

PE Ratio

84.3

Forward PE

87.3

PS Ratio

29.0

PB Ratio

10.6

EV/EBITDA

80.4

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Biotechnology

CEO

Xinshan Kang open_in_new

Employees

164

Founded

2012

Website

hxpharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
9.2%	23%	69%	86%	130%	92%	73%	73%	73%

News

Markets

Exchange	Ticker	Price	Quotes
Hong Kong Stock Exchange (SHEK / HKEX) MIC: XHKG PRIMARY	2637 ISIN: CNE100007515 Shares Out.: Shares Outstanding: 78.707M¹ Shares Float: 11.5M² TV: TradingView: HKEX: 2637 SA: Stock Analysis: HKG: 2637 YF: Yahoo Finance: 2637.HK GF: Google Finance: HKG: 2637 BA: Barron's: 2637 MS: Morningstar: XHKG: 02637	261.00 HKD	TV: TradingView: HKEX: 2637 SA: Stock Analysis: HKG: 2637 YF: Yahoo Finance: 2637.HK GF: Google Finance: HKG: 2637 BA: Barron's: 2637 MS: Morningstar: XHKG: 02637

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Fujian Haixi Pharmaceuticals Co., Ltd.

Fujian Haixi Pharmaceuticals Co., Ltd. manufactures and sells pharmaceutical drugs in China. The company offers drugs for oncology, ophthalmology, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It sells its products through retail pharmacies, online pharmacies, and internet medical platforms. The company was incorporated in 2012 and is based in Fuzhou, China.

Similar Companies

Industry: Biotechnology (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi Biologics (Cayman) Inc. SHEK: 2269	$17.44B 136.71B HKD 627%	25.3	China
CSPC Pharmaceutical Group Ltd. SHEK: 1093	$12.2B 95.58B HKD 408%	22.1	China
Sichuan Kelun Pharmaceutical Co., Ltd. SHE: 002422	$8.0B 54.23B CNY 233%	34.4	China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. SSE: 603392	$7.33B 49.69B CNY 206%	-	China
3SBio Inc. SHEK: 1530	$7.08B 55.5B HKD 195%	5.8	China
Hangzhou Tigermed Consulting Co., Ltd. SHE: 300347	$6.72B 45.52B CNY 180%	61.6	China

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 8K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 7K%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 2K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 2K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 2K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 2K%	37.2	Switzerland

chevron_leftBack